Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review

Gut Microbes. 2023 Dec;15(2):2287073. doi: 10.1080/19490976.2023.2287073.Epub 2023 Dec 3.


Susanna Meade 1 2Jeremy Liu Chen Kiow 1 2Cristian Massaro 3 4Gurpreet Kaur 2 3Elizabeth Squirell 1 2Brian Bressler 1 2Genelle Lunken 2 3 4


Author information

1Department of Medicine, University of British Columbia, Vancouver, Canada.

2IBD Centre of BC, Vancouver, Canada.

3Department of Pediatrics, Univerisity of British Columbia, Vancouver, Canada.


Loss of response to therapy in inflammatory bowel disease (IBD) has led to a surge in research focusing on precision medicine. Three systematic reviews have been published investigating the associations between gut microbiota and disease activity or IBD therapy. We performed a systematic review to investigate the microbiome predictors of response to advanced therapy in IBD. Unlike previous studies, our review focused on predictors of response to therapy; so the included studies assessed microbiome predictors before the proposed time of response or remission. We also provide an update of the available data on mycobiomes and viromes. We highlight key themes in the literature that may serve as future biomarkers of treatment response: the abundance of fecal SCFA-producing bacteria and opportunistic bacteria, metabolic pathways related to butyrate synthesis, and non-butyrate metabolomic predictors, including bile acids (BAs), amino acids, and lipids, as well as mycobiome predictors of response.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.